JP2021529519A5 - - Google Patents

Info

Publication number
JP2021529519A5
JP2021529519A5 JP2020572414A JP2020572414A JP2021529519A5 JP 2021529519 A5 JP2021529519 A5 JP 2021529519A5 JP 2020572414 A JP2020572414 A JP 2020572414A JP 2020572414 A JP2020572414 A JP 2020572414A JP 2021529519 A5 JP2021529519 A5 JP 2021529519A5
Authority
JP
Japan
Prior art keywords
composition according
composition
nucleic acid
single nucleic
clrn1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020572414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529519A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039030 external-priority patent/WO2020005974A1/en
Publication of JP2021529519A publication Critical patent/JP2021529519A/ja
Publication of JP2021529519A5 publication Critical patent/JP2021529519A5/ja
Priority to JP2023135405A priority Critical patent/JP2023153320A/ja
Priority to JP2025112689A priority patent/JP2025156349A/ja
Pending legal-status Critical Current

Links

JP2020572414A 2018-06-25 2019-06-25 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法 Pending JP2021529519A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023135405A JP2023153320A (ja) 2018-06-25 2023-08-23 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法
JP2025112689A JP2025156349A (ja) 2018-06-25 2025-07-03 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689660P 2018-06-25 2018-06-25
US62/689,660 2018-06-25
PCT/US2019/039030 WO2020005974A1 (en) 2018-06-25 2019-06-25 Methods of treating clrn1-associated hearing loss and/or vision loss

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135405A Division JP2023153320A (ja) 2018-06-25 2023-08-23 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法

Publications (2)

Publication Number Publication Date
JP2021529519A JP2021529519A (ja) 2021-11-04
JP2021529519A5 true JP2021529519A5 (enExample) 2022-06-24

Family

ID=68985009

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020572414A Pending JP2021529519A (ja) 2018-06-25 2019-06-25 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法
JP2023135405A Pending JP2023153320A (ja) 2018-06-25 2023-08-23 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法
JP2025112689A Pending JP2025156349A (ja) 2018-06-25 2025-07-03 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023135405A Pending JP2023153320A (ja) 2018-06-25 2023-08-23 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法
JP2025112689A Pending JP2025156349A (ja) 2018-06-25 2025-07-03 Clrn1に関連する聴力喪失及び/または視力喪失を治療する方法

Country Status (14)

Country Link
US (1) US20210277417A1 (enExample)
EP (1) EP3824090A4 (enExample)
JP (3) JP2021529519A (enExample)
KR (1) KR20210057720A (enExample)
CN (1) CN112639107B (enExample)
AU (2) AU2019294603B2 (enExample)
BR (1) BR112020026606A2 (enExample)
CA (1) CA3104330A1 (enExample)
CL (1) CL2020003346A1 (enExample)
EA (1) EA202190114A1 (enExample)
IL (1) IL279551A (enExample)
MX (1) MX2020013628A (enExample)
SG (1) SG11202012710WA (enExample)
WO (1) WO2020005974A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230340038A1 (en) * 2020-09-14 2023-10-26 President And Fellows Of Harvard College Recombinant adeno associated virus (raav) encoding gjb2 and uses thereof
IL304006A (en) * 2020-12-29 2023-08-01 Akouos Inc Compositions and methods for treating hearing loss and/or vision loss associated with CLRN1
EP4409009A4 (en) * 2021-09-30 2025-12-17 Akouos Inc Compositions for administering gene therapy and methods for treating hearing loss

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
WO2006084243A2 (en) * 2005-02-03 2006-08-10 Biotech Institute For International Innovation, Inc. Compositions and methods for the therapeutic treatment of diabetes
CA2624615A1 (en) * 2005-10-05 2007-04-19 Bayhill Therapeutics, Inc. Compositions and methods for treatment of autoimmune disease
US20090215178A1 (en) * 2008-02-22 2009-08-27 Zequn Tang Methods to enhance the stability and homogeneity of transgene expression in clonal cell lines
JP2013511258A (ja) * 2009-11-19 2013-04-04 株式会社免疫工学研究所 所望のポリペプチドを産生する抗体産生細胞の製造方法
MX362981B (es) * 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
CN102978284A (zh) * 2012-11-19 2013-03-20 金子兵 一种筛查各类眼科遗传性疾病的基因芯片及其制备和使用方法
EP2970972B1 (en) * 2013-03-11 2018-08-15 Fondazione Telethon Mir-204 and mir-211 and uses thereof
AU2014255665B2 (en) * 2013-04-18 2018-08-02 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
US11827680B2 (en) * 2014-11-06 2023-11-28 Case Western Reserve University Compounds and methods of treating usher syndrome III
BR112017026523A2 (pt) * 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
SG10201913266UA (en) * 2015-12-11 2020-02-27 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
EP3510161A4 (en) * 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON

Similar Documents

Publication Publication Date Title
JP2021513863A5 (enExample)
JP2021530227A5 (enExample)
JP2021529519A5 (enExample)
US9217020B2 (en) Constructs for enhancement of gene expression in muscle
AU2018352855B2 (en) Adeno-associated virus compositions for restoring HBB gene function and methods of use thereof
AU2010311376A1 (en) Cardiac-specific nucleic acid regulatory elements and methods and use thereof
US10729789B2 (en) Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
JP2021536250A5 (enExample)
IL292605B1 (en) CRISPR and AAV strategies for treating childhood X-linked retinoschisis
EP3188762A1 (en) High isomerohydrolase activity mutants of mammalian rpe65
CN104936606A (zh) 糖原贮积病的基因疗法
JP7752148B2 (ja) 筋強直性ジストロフィーの処置
JP2020535804A5 (enExample)
RS66227B1 (sr) Kompozicije i postupci za lečenje poremećaja mrežnjače
JP2021533801A5 (enExample)
US11096955B2 (en) Synthetic promoters and uses thereof
JP2023529371A (ja) シヌクレイノパチーの処置のための組成物および方法
EP4527933A1 (en) Dual-carrier system for treating hearing damage, and use thereof
WO2024069144A1 (en) Rna editing vector
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
JP2023549620A (ja) 組換え補体タンパク質を産生させる方法、そのベクターおよび治療的使用
EP1497306A1 (en) Alternatively spliced nucleic acid molecules
CN1152138C (zh) 一种腺相关病毒载体及其制备方法和用途
US20230279398A1 (en) Treating human t-cell leukemia virus by gene editing
WO2008074189A1 (en) A recombinant adenovirus comprising recombinant khp50 gene and preparation method and uses thereof